Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0025362 (
mental retardation
)
15,878
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
We have developed classification coefficients and an equation to detect heterozygotes for phenylketonuria. The combination of several variables (
Phe
,
Phe
/Tyr, Phe2/Tyr) gave a safe diagnosis in more than 96% of cases. We then computerized a random selection of our population, which was divided into two groups: the first was "selected" to compute discriminant functions, while the second, excluded from computation, was used to check the fitness of our method. Despite the reduction of sample size, 95.2% of unknown subjects were correctly classified. Finally, we used our equation to detect heterozygotes for phenylketonuria in a population of 26 children, affected by non-specific
mental retardation
, and their mothers. We found a high proportion of carriers for phenylketonuria, defined as subjects having a percent probability of correct classification higher than 90. By this method, heterozygosity was detected in two child-mother couples, four individual children and five mothers.
...
PMID:A simplified test to detect PKU heterozygotes by discriminant analysis in mentally retarded children and their mothers. 335 81
Young women with phenylketonuria (PKU) are at risk for bearing children with
mental retardation
, microcephaly, heart defects, and low birthweight. These effects may be prevented if a low
phenylalanine
diet is maintained prior to and throughout pregnancy. This report describes the procedures of the New England Regional Maternal PKU Project for identifying and locating this population of at-risk women. Newborn screening records, routine umbilical cord blood screening, and PKU Clinic records provided most of the identifying information. We identified 235 women with hyperphenylalaninemia, ages 12 to 44 years. Of these, 183 had PKU or atypical PKU while 52 had non-PKU mild hyperphenylalaninemia. The 235 women represent 88 per cent of the expected number of women with hyperphenylalaninemia in New England. We identified more than the expected number of those with PKU but only 57 per cent of the expected number with mild hyperphenylalaninemia. Developing a national registry, as well as screening women who utilize birth control clinics or prenatal clinics, may be helpful. Implementing routine umbilical cord blood screening programs may be beneficial in efforts to identify women with hyperphenylalaninemia who have had a child and may want more children in the future.
...
PMID:The New England Maternal PKU Project: identification of at-risk women. 338 53
Experimental hyperphenylalaninemia has been induced in 5-day-old chicks by dietary treatments with
phenylalanine
and alpha-methylphenylalanine. An increase of nearly 8-fold in plasma
Phe
/Tyr ratio was found after 4 days of supplementation the standard diet with 5%
phenylalanine
plus 0.4% alpha-methylphenylalanine. The increase in this ratio was about 13-fold after 9 days of the same treatment. Similar results were observed in brain and liver, although the increases were smaller than those found in plasma. Total body, brain and liver weight decreased after 9 days of treatment.
Phenylalanine
plus alpha-methylphenylalanine administration to 5-day-old chicks produced a significant decrease in the 3-hydroxy-3-methylglutaryl-CoA reductase and mevalonate-5-pyrophosphate decarboxylase specific activities from both brain and liver. These results demonstrated for the first time that experimental hyperphenylalaninemia inhibited different enzyme activities directly implicated in the regulation of cholesterogenesis. Therefore, a reduced cholesterol synthesis in brain may evidenciate the theory of an impaired myelination leading to
mental retardation
in phenylketonuria patients.
...
PMID:Inhibition of brain and liver 3-hydroxy-3-methylglutaryl-CoA reductase and mevalonate-5-pyrophosphate decarboxylase in experimental hyperphenylalaninemia. 340 80
Type II tyrosinemia (Richner-Hanhart syndrome) is a familial aminoacid disorder, clinically characterized by ocular changes (keratitis), palmo-plantar hyperkeratosis, no constant mental changes with mental deterioration, abnormal urinary excretion and high serum tyrosine level in consequence of the absence of tyrosine-aminotransferase. Almost 20 families have been described in the literature of which 50% are of Italian origin, suggesting that this disorder is particularly frequent in our country. We report a family with 2 affected members with typical clinical and biochemical findings (keratitis, palmo-plantar hyperkeratosis, abnormal urinary and serum tyrosine concentrations), not suffering from
mental retardation
. Clinical symptoms completely disappeared after the decrease of urinary and serum tyrosine levels following a tyrosine- and
phenylalanine
-free diet. These cases are compared with those reported in literature, and the usefulness of diet for the improvement of clinical and metabolic symptoms is discussed.
...
PMID:The effect of diet on the ophthalmological, clinical and biochemical aspects of Richner-Hanhart syndrome: a morphological ultrastructural study of the cornea and the conjunctiva. 365 59
Four women with classic phenylketonuria (blood
phenylalanine
greater than 1200 mumol/L) were given a
phenylalanine
-restricted diet; three also received L-tyrosine supplements. Biochemical measures of nutrition were normal except for iron deficiency anemia, and in one woman folate deficiency. One pregnancy in which treatment began before conception and another treated from 8 weeks gestation, both with blood
phenylalanine
levels maintained at 120 to 730 mumol/L, resulted in normal newborn infants whose postnatal growth and development have also been normal. A third pregnancy, treated from 6 gestational weeks, was marked by poor dietary compliance until the middle of the second trimester; fetal microcephaly was identified by ultrasonography at 28 weeks but not at 21 weeks. The child has microcephaly and motor delay. The fourth pregnancy, not treated until the third trimester, produced a child with microcephaly,
mental retardation
, hyperactivity, and neurologic deficits. It is likely that fetal damage from maternal phenylketonuria can be largely and perhaps entirely prevented by dietary therapy, but therapy must begin before conception for the best chance of a normal infant.
...
PMID:New England Maternal PKU Project: prospective study of untreated and treated pregnancies and their outcomes. 381 40
A defect in the synthesis of dihydrobiopterin was detected in an Arab girl, ascertained through high blood
phenylalanine
level on neonatal screening. An oral loading test with tetrahydrobiopterin (BH4) caused a significant fall in her blood
phenylalanine
and a rise in tyrosine concentrations. Her blood biopterin levels were low. In urine and cerebrospinal fluid (CSF) very high neopterin and low biopterin levels were observed. A deficiency of metabolites of neurotransmitters, serotonin and dopamine, was observed in CSF and urine. The patient was given replacement therapy of BH4, 5-hydroxytryptophan, and L-dopa with carbidopa starting from the age of 16 to 18 weeks. On this treatment the blood
phenylalanine
levels dropped to the desired range, while in urine and CSF a satisfactory rise of neurotransmitter metabolites was observed. In spite of this biochemical control, the patient developed neurological symptoms with myoclonic jerks and changes in muscle tone and presented severe cerebral damage with
mental retardation
. She died suddenly at the age of 38 weeks.
...
PMID:Malignant phenylketonuria due to defective synthesis of dihydrobiopterin. 387 52
Phenylketonuria provides a human model for the study of the effect of
phenylalanine
on brain function. Although irreversible
mental retardation
is preventable through newborn diagnosis and dietary
phenylalanine
restriction, controversy exists regarding the effects of increased concentrations of
phenylalanine
in older patients. We have studied ten older, treated, phenylketonuric patients using a triple-blind, multiple trials, crossover design. Each patient was tested at the end of each of three 1-wk periods of high or low
phenylalanine
intakes. Tests included a repeatable battery of neuropsychological tests, analysis of plasma amino acids, and measurement of urine amino acids, phenyl organic acids, dopamine, and serotonin. In all 10 patients plasma
phenylalanine
rose (900-4,000 microM). In 9 of 10 patients there was an inverse relationship between plasma
phenylalanine
and urine dopamine excretion. When blood
phenylalanine
was elevated, these patients had prolonged performance times on neuropsychological tests of higher but not lower integrative function. Urinary serotonin fell during
phenylalanine
loading in six patients. The concentration of phenylacids in the urine was not proportional to the plasma
phenylalanine
at concentrations below 1.5 mM. In one patient, neither performance time nor dopamine excretion varied as blood
phenylalanine
rose or fell. We interpret these data as follows: blood
phenylalanine
above 1.3 mM impairs performance on neuropsychological tests of higher integrative function, this effect is reversible, and one mechanism may involve impaired biogenic amine synthesis.
...
PMID:Biochemical and neuropsychological effects of elevated plasma phenylalanine in patients with treated phenylketonuria. A model for the study of phenylalanine and brain function in man. 388 Jul 75
The metabolites of
phenylalanine
, phenylacetate, phenyllactate, phenylpyruvate and phenylethylamine, were measured in the urine of PKU patients. In general correlation was found between serum
phenylalanine
excretion of these metabolites. However, there were individual variations in the quantities and type of metabolites excreted that could not be explained by blood
phenylalanine
levels. In a PKU pregnancy large quantities of
phenylalanine
metabolites were found in urine despite a modest elevation of serum
phenylalanine
. Increase in the excretion of
phenylalanine
metabolites was found in patients who were considered to have good blood
phenylalanine
control. These preliminary studies indicate that the current practice of allowing a wide range of blood
phenylalanine
in the treatment of PKU may have to be reexamined. Since these metabolites are neurotoxic, they may afford a new parameter for the study of PKU not only regarding the prevention of
mental retardation
but also with regards to behavior and learning disabilities.
...
PMID:Phenylalanine metabolites, attention span and hyperactivity. 402 5
To clarify the effects of perinatal anoxia on the subsequent amino acid metabolism in the brain of children, free amino acid levels in the cerebrospinal fluid (CSF) were determined in 15 children diagnosed as having cerebral palsy and/or
mental retardation
with perinatal anoxia, and 58 control children without anoxia, aged from 4 days to 12 yrs. There was no significant difference in total amino acid levels between anoxic children and the controls. In the controls, the Gln level in CSF was high, Arg, Asp and Glu levels in CSF were almost the same during infancy and childhood, and the levels of Orn, Lys, His, Tau, Thr, Ser, Asn, Gly, Ala, Val, Met, Ile, Leu, Tyr and
Phe
in CSF decreased with age until pre-school age. In the newborns and infants among the anoxic children, the levels of most free amino acids in CSF were relatively high compared with those of the controls and, except Glu and Gln, decreased with age during infancy. The Orn, His, Gly, Tyr and
Phe
levels in CSF of anoxic children were lower than those of the controls in older infants. These results suggest that perinatal anoxia affected free amino acid patterns in CSF of newborns and infants and that the subsequent disturbance of amino acid metabolism in their brains remained after birth.
...
PMID:The effect of perinatal anoxia on amino acid metabolism in the developing brain. Part II: The effect of perinatal anoxia on the free amino acid patterns in CSF of infants and children. 406 76
1. Inhibition of the rate of incorporation of [(35)S]methionine into protein by
phenylalanine
was more effective in 18-day-old than in 8-day-old or adult rat brain. 2. Among the subcellular fractions incorporation of [(35)S]methionine into myelin proteins was most inhibited in 18-day-old rat brain. 3. Transport of [(35)S]methionine and [(14)C]leucine into the brain acid-soluble pool was significantly decreased in 18-day-old rats by
phenylalanine
(2mg/g body wt.). The decrease of the two amino acids in the acid-soluble pool equalled the inhibition of their rate of incorporation into the protein. 4. Under identical conditions, entry of [(14)C]glycine into the brain acid-soluble pool and incorporation into protein and uptake of [(14)C]acetate into lipid was not affected by
phenylalanine
. 5. It is proposed that decreased myelin synthesis seen in hyperphenylalaninaemia or phenylketonuria may be due to alteration of the free amino acid pool in the brain during the vulnerable period of brain development. Amyelination may be one of many causes of
mental retardation
seen in phenylketonuria.
...
PMID:Effect of phenylalanine on protein synthesis in the developing rat brain. 546 65
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>